Chugai Pharmaceutical

Global Pricing Cuts And Pipeline Delays Will Dim Prospects

AnalystLowTarget

Not Invested

Consensus Narrative from 14 Analysts

Published

04 Jun 25

Updated

09 Aug 25

AnalystLowTarget's Fair Value

JP¥6,100.00

4.6% overvalued

09 Aug

JP¥6,380.00

-13.0%

-0.9%

-13.0%

-0.9%

Author's Valuation

JP¥6.1k

4.6% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

JP¥6.1k

4.6% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.62%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.72%

Calculation

JP¥428.60b

Earnings '28

26.90x

PE Ratio '28

JP¥11.53t

Market Cap '28

JP¥11.53t

Market Cap '28

1.65b

No. shares '28

JP¥7.00k

Share Price '28

JP¥7.00k Share Price '28

Discounted to 2025 @ 4.72% p.a.

JP¥6.10k

Fair Value '25